Abstract
In order to identify proteins that bind to the PDZ domain of Erbin, we tested the C-termini of several proteins in a yeast two-hybrid assay. ErbB2, APC, β-catenin, c-Rel and HTLV-1 Tax were identified as ligands of the PDZ domain of Erbin. The interactions were verified by co-immunoprecipitation experiments. These findings demonstrate the promiscuity of the PDZ domain of Erbin.
Keywords: Erbin, PDZ domain, ErbB2, APC, c-Rel, HTLV-1 Tax
Protein & Peptide Letters
Title: Interaction Partners of the PDZ Domain of Erbin
Volume: 13 Issue: 9
Author(s): Angelika Ress and Karin Moelling
Affiliation:
Keywords: Erbin, PDZ domain, ErbB2, APC, c-Rel, HTLV-1 Tax
Abstract: In order to identify proteins that bind to the PDZ domain of Erbin, we tested the C-termini of several proteins in a yeast two-hybrid assay. ErbB2, APC, β-catenin, c-Rel and HTLV-1 Tax were identified as ligands of the PDZ domain of Erbin. The interactions were verified by co-immunoprecipitation experiments. These findings demonstrate the promiscuity of the PDZ domain of Erbin.
Export Options
About this article
Cite this article as:
Ress Angelika and Moelling Karin, Interaction Partners of the PDZ Domain of Erbin, Protein & Peptide Letters 2006; 13 (9) . https://dx.doi.org/10.2174/092986606778256126
DOI https://dx.doi.org/10.2174/092986606778256126 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heregulin in Breast Cancer: Old Story, New Paradigm
Current Pharmaceutical Design Synthesis and Biological Activity of Pyrazolo[4,3-c]heterocyclic Derivatives: A Mini Review
Mini-Reviews in Organic Chemistry Breast Cancer Stem Cells and Intrinsic Subtypes: Controversies Rage On
Current Stem Cell Research & Therapy Crosstalk Between Bioactive Peptide and Intestinal Barrier in Gut Homeostasis
Current Protein & Peptide Science Novel Inhibitory Activity for Serine Protease Inhibitor Kazal Type-3 (Spink3) on Human Recombinant Kallikreins
Protein & Peptide Letters Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design Targeting the Ribosome Biogenesis Key Molecule Fibrillarin to Avoid Chemoresistance
Current Medicinal Chemistry From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design Dual Modulators of p53 and Cyclin D in ER Alpha Signaling by Albumin Nanovectors Bearing Zinc Chaperones for ER-positive Breast Cancer Therapy
Mini-Reviews in Medicinal Chemistry Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy Accessing the Blood-Brain Barrier to Treat Brain Disorders
Current Nanomedicine Modelling Human Disease with Pluripotent Stem Cells
Current Gene Therapy Susceptibility Risk Alleles of -238G/A, -308G/A and -1031T/C Promoter Polymorphisms of TNF-α Gene to Uterine Leiomyomas
Recent Advances in DNA & Gene Sequences (Discontinued) Brief Messages to Promote Prevention and Detection of Sexually Transmitted Infections
Current HIV Research Review of Rational Approaches to the Treatment of Pain Management-Role forOpioids Therapies
Current Drug Therapy Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target
Mini-Reviews in Medicinal Chemistry Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Recent Patents in siRNA Delivery Employing Nanoparticles as Delivery Vectors
Recent Patents on DNA & Gene Sequences Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression
Current HIV Research Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer
Current Pharmaceutical Design